| 1 | Targeting fibroblast phenotype switching in cardiac remodelling as a promising antifibrotic strategy | 2.2 | 20 | Citations (PDF) |
| 2 | Integration of genetic testing into diagnostic pathways for cardiomyopathies: a clinical consensus statement by the ESC Council on Cardiovascular Genomics | 2.2 | 31 | Citations (PDF) |
| 3 | Prolonged Hypoxia in Rat Living Myocardial Slices Affects Function, Expression, and Structure | 4.4 | 10 | Citations (PDF) |
| 4 | Anti-senescence therapies: a new concept to address cardiovascular disease | 5.5 | 24 | Citations (PDF) |
| 5 | Myosin-5b: the overlooked motor of cardiac health? | 2.2 | 1 | Citations (PDF) |
| 6 | Living myocardial slices: walking the path towards standardization | 5.5 | 9 | Citations (PDF) |
| 7 | Development of a microarray based telomerase binding assay reveals unusual binding of a cytochalasin derivative | 3.4 | 0 | Citations (PDF) |
| 8 | Exploring hiPSC-CM replacement therapy in ischemic hearts | 7.0 | 0 | Citations (PDF) |
| 9 | Generation of a human induced pluripotent stem cell reporter line to investigate cell division and proliferation | 0.6 | 0 | Citations (PDF) |
| 10 | MiR-132 inhibition improves myocardial strain in a large animal model of chronic left ventricular adverse remodelling 2025, 3, | | 2 | Citations (PDF) |
| 11 | Macrophage-based therapeutic approaches for cardiovascular diseases | 7.0 | 46 | Citations (PDF) |
| 12 | LIPCAR levels in plasma-derived extracellular vesicles is associated with left ventricle remodeling post-myocardial infarction | 6.4 | 22 | Citations (PDF) |
| 13 | Dextrans, Pullulan and Lentinan, New Scaffold Materials for Use as Hydrogels in Tissue Engineering | 3.4 | 4 | Citations (PDF) |
| 14 | A pilot study for risk stratification of ventricular tachyarrhythmia in hypertrophic cardiomyopathy with routine echocardiography parameters | 3.4 | 1 | Citations (PDF) |
| 15 | Circulating miR-let7a levels predict future diagnosis of chronic thromboembolic pulmonary hypertension | 3.4 | 6 | Citations (PDF) |
| 16 | Inhibition of miR-21: cardioprotective effects in human failing myocardium ex vivo | 2.2 | 21 | Citations (PDF) |
| 17 | The role of fibrosis in cardiomyopathies: An opportunity to develop novel biomarkers of disease activity | 4.5 | 7 | Citations (PDF) |
| 18 | Circular RNA circZFPM2 regulates cardiomyocyte hypertrophy and survival | 7.0 | 18 | Citations (PDF) |
| 19 | CRISPR/Cas9-based GLA knockout to generate the female Fabry disease human induced pluripotent stem cell line MHHi001-A-15 | 0.6 | 1 | Citations (PDF) |
| 20 | Circulating long noncoding RNA PDE4DIPP6: A novel biomarker for improving the clinical management of non-ST-segment elevation myocardial infarction | 1.5 | 4 | Citations (PDF) |
| 21 | Discontinuation of afterload-reducing drugs decreases left ventricular outflow tract obstruction in hypertrophic obstructive cardiomyopathy | 2.4 | 3 | Citations (PDF) |
| 22 | SGLT2 inhibitors attenuate endothelial to mesenchymal transition and cardiac fibroblast activation | 3.4 | 19 | Citations (PDF) |
| 23 | Single-nucleus RNA sequencing identifies cell-type–specific effects of sodium-glucose co-transporter 2 inhibitors in human myocardial slices | 2.2 | 14 | Citations (PDF) |
| 24 | A reporter system for live cell tracking of human cardiomyocyte proliferation | 5.5 | 2 | Citations (PDF) |
| 25 | Human in vitro models for Fabry disease: new paths for unravelling disease mechanisms and therapies | 6.4 | 7 | Citations (PDF) |
| 26 | Automated High-Throughput Live Cell Monitoring of Scratch Wound Closure | 2.6 | 5 | Citations (PDF) |
| 27 | Methods for the identification and characterization of extracellular vesicles in cardiovascular studies: from exosomes to microvesicles | 5.5 | 158 | Citations (PDF) |
| 28 | Emerging epigenetic therapies of cardiac fibrosis and remodelling in heart failure: from basic mechanisms to early clinical development | 5.5 | 77 | Citations (PDF) |
| 29 | Circular RNAs at the intersection of cancer and heart disease: potential therapeutic targets in cardio-oncology | 5.5 | 14 | Citations (PDF) |
| 30 | An exploratory approach to identify microRNAs as circulatory biomarker candidates for epilepsy-associated psychiatric comorbidities in an electrical post-status epilepticus model | 3.4 | 0 | Citations (PDF) |
| 31 | A single session of EMS training induces long-lasting changes in circulating muscle but not cardiovascular miRNA levels: a randomized crossover study | 2.8 | 9 | Citations (PDF) |
| 32 | COVID-19: Insights into long-term manifestations and lockdown impacts | 7.4 | 8 | Citations (PDF) |
| 33 | Identification of Gene Expression Signatures for Phenotype-Specific Drug Targeting of Cardiac Fibrosis | 4.4 | 2 | Citations (PDF) |
| 34 | Blood Biomarkers in Takotsubo Syndrome Point to an Emerging Role for Inflammaging in Endothelial Pathophysiology | 4.2 | 3 | Citations (PDF) |
| 35 | Skeletal muscle fiber hypercontraction induced by Bothrops asper myotoxic phospholipases A2 ex vivo does not involve a direct action on the contractile apparatus | 2.3 | 4 | Citations (PDF) |
| 36 | Myosin expression and contractile function are altered by replating stem cell–derived cardiomyocytes | 2.4 | 8 | Citations (PDF) |
| 37 | Acute heart failure: mechanisms and pre-clinical models—a Scientific Statement of the ESC Working Group on Myocardial Function | 5.5 | 6 | Citations (PDF) |
| 38 | Incidence, Risk Assessment and Prevention of Sudden Cardiac Death in Cardiomyopathies | 7.3 | 31 | Citations (PDF) |
| 39 | Development of a Mechanism-Based Next-Generation Therapeutic for Heart Failure Derived From the Dark Genome | 3.3 | 6 | Citations (PDF) |
| 40 | Dissecting the transcriptome in cardiovascular disease | 5.5 | 38 | Citations (PDF) |
| 41 | Alternative strategies in cardiac preclinical research and new clinical trial formats | 5.5 | 29 | Citations (PDF) |
| 42 | Remodelling of adult cardiac tissue subjected to physiological and pathological mechanical load in vitro | 5.5 | 53 | Citations (PDF) |
| 43 | Circulating microRNAs predispose to takotsubo syndrome following high-dose adrenaline exposure | 5.5 | 51 | Citations (PDF) |
| 44 | Prognostic value of circulating microRNAs compared to high-sensitivity troponin T in patients presenting with suspected acute coronary syndrome to the emergency department | 1.8 | 5 | Citations (PDF) |
| 45 | Pathophysiology of Takotsubo syndrome – a joint scientific statement from the Heart Failure Association Takotsubo Syndrome Study Group and Myocardial Function Working Group of the European Society of Cardiology – Part 2: vascular pathophysiology, gender and sex hormones, genetics, chronic cardiovascular problems and clinical implications | 7.3 | 61 | Citations (PDF) |
| 46 | Non-coding RNAs: key regulators of reprogramming, pluripotency, and cardiac cell specification with therapeutic perspective for heart regeneration | 5.5 | 26 | Citations (PDF) |
| 47 | The long non-coding RNA NRON promotes the development of cardiac hypertrophy in the murine heart | 10.2 | 22 | Citations (PDF) |
| 48 | Comprehensive Expression Analysis of Cardiac Fibroblast Growth Factor 23 in Health and Pressure-induced Cardiac Hypertrophy | 3.6 | 15 | Citations (PDF) |
| 49 | Targeted therapies in genetic dilated and hypertrophic cardiomyopathies: from molecular mechanisms to therapeutic targets. A position paper from the Heart Failure Association (HFA) and the Working Group on Myocardial Function of the European Society of Cardiology (ESC) | 7.3 | 51 | Citations (PDF) |
| 50 | Animal models and animal-free innovations for cardiovascular research: current status and routes to be explored. Consensus document of the ESC Working Group on Myocardial Function and the ESC Working Group on Cellular Biology of the Heart | 5.5 | 75 | Citations (PDF) |
| 51 | Skeletal muscle derived Musclin protects the heart during pathological overload | 13.7 | 73 | Citations (PDF) |
| 52 | miR-486 attenuates cardiac ischemia/reperfusion injury and mediates the beneficial effect of exercise for myocardial protection | 10.2 | 95 | Citations (PDF) |
| 53 | Interpretation and actionability of genetic variants in cardiomyopathies: a position statement from the European Society of Cardiology Council on cardiovascular genomics | 2.2 | 65 | Citations (PDF) |
| 54 | Pathophysiology of
T
akotsubo syndrome – a joint scientific statement from the Heart Failure Association
T
akotsubo Syndrome Study Group and Myocardial Function Working Group of the
E
uropean Society of Cardiology – Part 1: overview and the central role for catecholamines and sympathetic nervous system | 7.3 | 74 | Citations (PDF) |
| 55 | Cardiac remodelling – Part 1: From cells and tissues to circulating biomarkers. A review from the Study Group on Biomarkers of the Heart Failure Association of the European Society of Cardiology | 7.3 | 63 | Citations (PDF) |
| 56 | Nicht kodierende Ribonukleinsäure im kardiovaskulären System | 0.2 | 0 | Citations (PDF) |
| 57 | Renal effects of guideline‐directed medical therapies in heart failure: a consensus document from the Heart Failure
Association of the European Society of Cardiology | 7.3 | 130 | Citations (PDF) |
| 58 | Development and characterization of anti-fibrotic natural compound similars with improved effectivity | 7.0 | 18 | Citations (PDF) |
| 59 | Orchestration of vascular smooth muscle cell plasticity using epigenetic therapy | 2.2 | 2 | Citations (PDF) |
| 60 | Neonatal injury models: integral tools to decipher the molecular basis of cardiac regeneration | 7.0 | 20 | Citations (PDF) |
| 61 | MicroRNA-449a Inhibits Triple Negative Breast Cancer by Disturbing DNA Repair and Chromatid Separation | 4.4 | 11 | Citations (PDF) |
| 62 | Deciphering Pro-angiogenic Transcription Factor Profiles in Hypoxic Human Endothelial Cells by Combined Bioinformatics and in vitro Modeling | 2.4 | 3 | Citations (PDF) |
| 63 | Biomarkers for the prediction of heart failure and cardiovascular events in patients with type 2 diabetes: a position statement from the Heart Failure Association of the European Society of Cardiology | 7.3 | 22 | Citations (PDF) |
| 64 | A circular RNA derived from the insulin receptor locus protects against doxorubicin-induced cardiotoxicity | 2.2 | 101 | Citations (PDF) |
| 65 | AAV capsid engineering identified two novel variants with improved in vivo tropism for cardiomyocytes | 10.2 | 44 | Citations (PDF) |
| 66 | Accelerating cardiovascular research: recent advances in translational
2D
and
3D
heart models | 7.3 | 50 | Citations (PDF) |
| 67 | Longitudinal characterization of clinically relevant haemodynamics in conscious Ossabaw pigs with HFpEF | 2.2 | 0 | Citations (PDF) |
| 68 | Molecular Mechanisms of Takotsubo Syndrome | 4.4 | 19 | Citations (PDF) |
| 69 | Chemical and mechanical activation of resident cardiac macrophages in the living myocardial slice ex vivo model | 7.0 | 17 | Citations (PDF) |
| 70 | Accelerating developments in heart failure | 5.5 | 2 | Citations (PDF) |
| 71 | Towards standardization of echocardiography for the evaluation of left ventricular function in adult rodents: a position paper of the ESC Working Group on Myocardial Function | 5.5 | 192 | Citations (PDF) |
| 72 | CDR132L improves systolic and diastolic function in a large animal model of chronic heart failure | 2.2 | 137 | Citations (PDF) |
| 73 | Novel antisense therapy targeting microRNA-132 in patients with heart failure: results of a first-in-human Phase 1b randomized, double-blind, placebo-controlled study | 2.2 | 352 | Citations (PDF) |
| 74 | Pharmacokinetics and Proceedings in Clinical Application of Nucleic Acid Therapeutics | 10.2 | 51 | Citations (PDF) |
| 75 | Combined high-throughput library screening and next generation RNA sequencing uncover microRNAs controlling human cardiac fibroblast biology | 3.8 | 12 | Citations (PDF) |
| 76 | Diagnostic value of circulating microRNAs compared to high-sensitivity troponin T for the detection of non-ST-segment elevation myocardial infarction | 1.0 | 14 | Citations (PDF) |
| 77 | Blood-based protein profiling identifies serum protein c-KIT as a novel biomarker for hypertrophic cardiomyopathy | 3.4 | 11 | Citations (PDF) |
| 78 | Renal AAV2-Mediated Overexpression of Long Non-Coding RNA H19 Attenuates Ischemic Acute Kidney Injury Through Sponging of microRNA-30a-5p | 0.4 | 61 | Citations (PDF) |
| 79 | LIPCAR Is Increased in Chronic Symptomatic HF Patients. A Sub-Study of the GISSI-HF Trial | 1.1 | 18 | Citations (PDF) |
| 80 | Role of endothelial microRNA 155 on capillary leakage in systemic inflammation | 6.0 | 15 | Citations (PDF) |
| 81 | Risk stratification and management of women with cardiomyopathy/heart failure planning pregnancy or presenting during/after pregnancy: a position statement from the Heart Failure Association of the European Society of Cardiology Study Group on Peripartum Cardiomyopathy | 7.3 | 71 | Citations (PDF) |
| 82 | Circulating cardiovascular
microRNAs
in critically ill
COVID
‐19 patients | 7.3 | 135 | Citations (PDF) |
| 83 | Cardiovascular RNA markers and artificial intelligence may improve COVID-19 outcome: a position paper from the EU-CardioRNA COST Action CA17129 | 5.5 | 23 | Citations (PDF) |
| 84 | Therapeutic and Diagnostic Translation of Extracellular Vesicles in Cardiovascular Diseases | 18.0 | 193 | Citations (PDF) |
| 85 | Telomerase therapy attenuates cardiotoxic effects of doxorubicin | 10.2 | 61 | Citations (PDF) |
| 86 | Patient profiling in heart failure for tailoring medical therapy. A consensus document of the
Heart Failure Association of the European Society of Cardiology | 7.3 | 251 | Citations (PDF) |
| 87 | FC 018HIGH DIETARY PHOSPHATE INTAKE AND INTRA-CARDIAC SYNTHESIS OF FIBROBLAST GROWTH FACTOR 23 SYNERGISTICALLY WORSEN CARDIAC FUNCTION | 0.8 | 0 | Citations (PDF) |
| 88 | Leveraging clinical epigenetics in heart failure with preserved ejection fraction: a call for individualized therapies | 2.2 | 51 | Citations (PDF) |
| 89 | Heart Failure Association of the ESC, Heart Failure Society of America and Japanese Heart Failure Society Position statement on endomyocardial biopsy | 7.3 | 206 | Citations (PDF) |
| 90 | AntimiR-132 Attenuates Myocardial Hypertrophy in an Animal Model of Percutaneous Aortic Constriction | 2.3 | 76 | Citations (PDF) |
| 91 | Reconstruction of the miR-506-Quaking axis in Idiopathic Pulmonary Fibrosis using integrative multi-source bioinformatics | 3.4 | 9 | Citations (PDF) |
| 92 | Serum microRNAs and antifibrotic response to eplerenone in acute myocardial infarction complicated by systolic dysfunction | 2.2 | 7 | Citations (PDF) |
| 93 | Heart Failure Association, Heart Failure Society of America, and Japanese Heart Failure Society Position Statement on Endomyocardial Biopsy | 1.8 | 58 | Citations (PDF) |
| 94 | ERBB4 and Multiple MicroRNAs That Target ERBB4 Participate in Pregnancy-Related Cardiomyopathy | 4.4 | 20 | Citations (PDF) |
| 95 | Reply to ‘
COVID
‐19 severity,
miR
‐21 targets, and common human genetic variation’ | 7.3 | 5 | Citations (PDF) |
| 96 | Genomic instability in the naturally and prematurely aged myocardium | 7.5 | 33 | Citations (PDF) |
| 97 | Circulating miR-185-5p as a Potential Biomarker for Arrhythmogenic Right Ventricular Cardiomyopathy | 4.6 | 14 | Citations (PDF) |
| 98 | MicroRNAs bei COVID-19: kleine Moleküle mit großem Potenzial? | 0.1 | 1 | Citations (PDF) |
| 99 | Novel aspects of age-protection by spermidine supplementation are associated with preserved telomere length | 4.6 | 36 | Citations (PDF) |
| 100 | Reciprocal organ interactions during heart failure: a position paper from the ESC Working Group on Myocardial Function | 5.5 | 51 | Citations (PDF) |
| 101 | DGK and DZHK position paper on genome editing: basic science applications and future perspective | 7.0 | 8 | Citations (PDF) |
| 102 | COVID
‐19 vaccination in patients with heart failure: a position paper of the Heart Failure Association of the European Society of Cardiology | 7.3 | 51 | Citations (PDF) |
| 103 | Diagnostic value of circulating microRNAs compared to high-sensitivity troponin T for the detection of non-ST-segment elevation myocardial infarction | 2.2 | 0 | Citations (PDF) |
| 104 | Artificial Intelligence Identifies an Urgent Need for Peripheral Vascular Intervention by Multiplexing Standard Clinical Parameters | 3.4 | 14 | Citations (PDF) |
| 105 | Cardiac Fibroblast Growth Factor 23 Excess Does Not Induce Left Ventricular Hypertrophy in Healthy Mice | 3.6 | 19 | Citations (PDF) |
| 106 | Circulating microRNAs in Symptomatic and Asymptomatic Carotid Stenosis | 2.3 | 6 | Citations (PDF) |
| 107 | COVID-19: Winzige Moleküle belegen Herz- und Gefäßbeteiligung 2021, , | | 0 | Citations (PDF) |
| 108 | A comprehensive method protocol for annotation and integrated functional understanding of lncRNAs | 6.6 | 7 | Citations (PDF) |
| 109 | Non‐coding RNAs: key players in cardiac disease | 3.4 | 34 | Citations (PDF) |
| 110 | In peripartum cardiomyopathy plasminogen activator inhibitor-1 is a potential new biomarker with controversial roles | 5.5 | 38 | Citations (PDF) |
| 111 | Living myocardial slices: a novel multicellular model for cardiac translational research | 2.2 | 43 | Citations (PDF) |
| 112 | European Society of Cardiology/Heart Failure Association Position Paper on the Role and Safety of New Glucose-Lowering Drugs in Patients with Heart Failure | 7.3 | 152 | Citations (PDF) |
| 113 | Senescence-induced inflammation: an important player and key therapeutic target in atherosclerosis | 2.2 | 168 | Citations (PDF) |
| 114 | Heart Failure Association of the European Society of Cardiology Update on Sodium–Glucose Co-Transporter 2 Inhibitors in Heart Failure | 7.3 | 77 | Citations (PDF) |
| 115 | Circulating miR-216a as a biomarker of metabolic alterations and obesity in women | 4.6 | 16 | Citations (PDF) |
| 116 | MicroRNAs as systemic biomarkers to assess distress in animal models for gastrointestinal diseases | 3.4 | 5 | Citations (PDF) |
| 117 | Targeting muscle-enriched long non-coding RNA H19 reverses pathological cardiac hypertrophy | 2.2 | 118 | Citations (PDF) |
| 118 | Cardiac dysfunction in cancer patients: beyond direct cardiomyocyte damage of anticancer drugs: novel cardio-oncology insights from the joint 2019 meeting of the ESC Working Groups of Myocardial Function and Cellular Biology of the Heart | 5.5 | 84 | Citations (PDF) |
| 119 | Debating new strategies for cardiac protection in the ageing heart in Naples, Italy: news from the joint meeting of the ESC Working Groups of Myocardial Function and Cellular Biology of the Heart | 5.5 | 0 | Citations (PDF) |
| 120 | Improved cardiovascular risk prediction in patients with end-stage renal disease on hemodialysis using machine learning modeling and circulating microribonucleic acids | 11.3 | 35 | Citations (PDF) |
| 121 | Using “old” medications to fight new COVID-19: Re-purposing with a purpose | 3.8 | 1 | Citations (PDF) |
| 122 | Non-coding RNAs: emerging players in cardiomyocyte proliferation and cardiac regeneration | 7.0 | 71 | Citations (PDF) |
| 123 | Common Mechanistic Pathways in Cancer and Heart Failure. A Scientific Roadmap on Behalf of the Translational Research Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC) | 7.3 | 169 | Citations (PDF) |
| 124 | Aging impairs alveolar epithelial type II cell function in acute lung injury | 3.2 | 49 | Citations (PDF) |
| 125 | A practical guide for investigating cardiac physiology using living myocardial slices | 7.0 | 29 | Citations (PDF) |
| 126 | MicroRNAs targeting the SARS-CoV-2 entry receptor ACE2 in cardiomyocytes | 3.8 | 102 | Citations (PDF) |
| 127 | Association between Circular RNA CDR1as and Post-Infarction Cardiac Function in Pig Ischemic Heart Failure: Influence of the Anti-Fibrotic Natural Compounds Bufalin and Lycorine | 4.2 | 38 | Citations (PDF) |
| 128 | Assessment of Major Mental Disorders in a German Peripartum Cardiomyopathy Cohort | 3.1 | 31 | Citations (PDF) |
| 129 | Resident cardiac macrophages: crucial modulators of cardiac (patho)physiology | 7.0 | 47 | Citations (PDF) |
| 130 | The Institute of Molecular and Translational Therapeutic Strategies, Hannover Medical School, Germany | 2.2 | 0 | Citations (PDF) |
| 131 | Cardiac endurance training alters plasma profiles of circular RNA MBOAT2 | 3.5 | 22 | Citations (PDF) |
| 132 | Dichotomy between the transcriptomic landscape of naturally versus accelerated aged murine hearts | 3.4 | 4 | Citations (PDF) |
| 133 | SARS-CoV-2 receptor ACE2 expression in the human heart: cause of a post-pandemic wave of heart failure? | 2.2 | 36 | Citations (PDF) |
| 134 | Cardiomyocyte ageing and cardioprotection: consensus document from the ESC working groups cell biology of the heart and myocardial function | 5.5 | 59 | Citations (PDF) |
| 135 | Stimulating pro-reparative immune responses to prevent adverse cardiac remodelling: consensus document from the joint 2019 meeting of the ESC Working Groups of cellular biology of the heart and myocardial function | 5.5 | 34 | Citations (PDF) |
| 136 | Baseline Cardiovascular Risk Assessment in Cancer Patients Scheduled to Receive Cardiotoxic Cancer Therapies: A Position Statement and New Risk Assessment Tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in Collaboration with the International Cardio-Oncology Society | 7.3 | 714 | Citations (PDF) |
| 137 | Comprehensive Bioinformatics Identifies Key microRNA Players in ATG7-Deficient Lung Fibroblasts | 4.4 | 12 | Citations (PDF) |
| 138 | Inflammatory Drivers of Cardiovascular Disease: Molecular Characterization of Senescent Coronary Vascular Smooth Muscle Cells | 2.8 | 44 | Citations (PDF) |
| 139 | The ESC Working Group on Myocardial Function | 2.2 | 0 | Citations (PDF) |
| 140 | Integrative Bioinformatic Analyses of Global Transcriptome Data Decipher Novel Molecular Insights into Cardiac Anti-Fibrotic Therapies | 4.4 | 17 | Citations (PDF) |
| 141 | Non-coding RNAs: update on mechanisms and therapeutic targets from the ESC Working Groups of Myocardial Function and Cellular Biology of the Heart | 5.5 | 53 | Citations (PDF) |
| 142 | Pleiotropic cardiac functions controlled by ischemia-induced lncRNA H19 | 3.8 | 23 | Citations (PDF) |
| 143 | Sodium–Glucose Co-Transporter 2 Inhibitors in Heart Failure: Beyond Glycaemic Control. A Position Paper of the Heart Failure Association of the European Society of Cardiology | 7.3 | 117 | Citations (PDF) |
| 144 | Role of Cardiovascular Imaging in Cancer Patients Receiving Cardiotoxic Therapies: A Position Statement on Behalf of the Heart Failure Association (HFA), the European Association of Cardiovascular Imaging (EACVI) and the Cardio-Oncology Council of the European Society of Cardiology (ESC) | 7.3 | 334 | Citations (PDF) |
| 145 | Preclinical and Clinical Development of Noncoding RNA Therapeutics for Cardiovascular Disease | 13.1 | 202 | Citations (PDF) |
| 146 | Plasma circular RNA hsa_circ_0001445 and coronary artery disease: Performance as a biomarker | 0.6 | 105 | Citations (PDF) |
| 147 | Preclinical development of a miR-132 inhibitor for heart failure treatment | 13.7 | 193 | Citations (PDF) |
| 148 | Natural Compound Library Screening Identifies New Molecules for the Treatment of Cardiac Fibrosis and Diastolic Dysfunction | 18.0 | 79 | Citations (PDF) |
| 149 | Acute Coronary Syndromes and Acute Heart Failure: A Diagnostic Dilemma and High-Risk Combination. A Statement from the Acute Heart Failure Committee of the Heart Failure Association of the European Society of Cardiology | 7.3 | 85 | Citations (PDF) |
| 150 | Omics phenotyping in heart failure: the next frontier | 2.2 | 67 | Citations (PDF) |
| 151 | SARS-CoV-2 receptor ACE2-dependent implications on the cardiovascular system: From basic science to clinical implications | 3.8 | 122 | Citations (PDF) |
| 152 | Non-coding RNAs: Regulators of valvular calcification | 3.8 | 14 | Citations (PDF) |
| 153 | miR−21 and NT-proBNP Correlate with Echocardiographic Parameters of Atrial Dysfunction and Predict Atrial Fibrillation | 2.5 | 32 | Citations (PDF) |
| 154 | MiRNA-181a is a Novel Regulator of Aldosterone–Mineralocorticoid Receptor-Mediated Cardiac Remodelling | 7.3 | 46 | Citations (PDF) |
| 155 | Pharmacokinetic Studies of Antisense Oligonucleotides Using MALDI-TOF Mass Spectrometry | 3.8 | 4 | Citations (PDF) |
| 156 | AntimiR-21 Prevents Myocardial Dysfunction in a Pig Model of Ischemia/Reperfusion Injury | 2.3 | 124 | Citations (PDF) |
| 157 | miR-21, Mediator, and Potential Therapeutic Target in the Cardiorenal Syndrome | 3.8 | 45 | Citations (PDF) |
| 158 | miR-21-KO Alleviates Alveolar Structural Remodeling and Inflammatory Signaling in Acute Lung Injury | 4.4 | 17 | Citations (PDF) |
| 159 | Letter by Pinet et al Regarding Article, “Comparative Analysis of Circulating Noncoding RNAs Versus Protein Biomarkers in the Detection of Myocardial Injury” | 13.1 | 2 | Citations (PDF) |
| 160 | Selective Heart Irradiation Induces Cardiac Overexpression of the Pro-hypertrophic miR-212 | 2.6 | 29 | Citations (PDF) |
| 161 | FO083CHRONIC FGF23 OVERLOAD FAILS TO INDUCE CARDIAC DYSFUNCTIONS | 0.8 | 1 | Citations (PDF) |
| 162 | Circular RNAs: A Novel Class of Functional RNA Molecules with a Therapeutic Perspective | 10.2 | 259 | Citations (PDF) |
| 163 | A new diastolic dysfunction disease-modelling platform | 2.2 | 1 | Citations (PDF) |
| 164 | A novel multi-parametric analysis of non-invasive methods to assess animal distress during chronic pancreatitis | 3.4 | 23 | Citations (PDF) |
| 165 | TIP
30 counteracts cardiac hypertrophy and failure by inhibiting translational elongation | 7.1 | 28 | Citations (PDF) |
| 166 | Attenuated palmitoylation of serotonin receptor 5-HT1A affects receptor function and contributes to depression-like behaviors | 13.7 | 136 | Citations (PDF) |
| 167 | FP280FUNCTIONAL INVESTIGATION OF MIR-17-5P INHIBITION IN KIDNEY ISCHEMIA-REPERFUSION INJURY IN MICE | 0.8 | 0 | Citations (PDF) |
| 168 | Long Noncoding RNA-Enriched Vesicles Secreted by Hypoxic Cardiomyocytes Drive Cardiac Fibrosis | 5.5 | 111 | Citations (PDF) |
| 169 | Studying Interactions between 2’-O-Me-Modified Inhibitors and MicroRNAs Utilizing Microscale Thermophoresis | 5.5 | 7 | Citations (PDF) |
| 170 | Circulating Long Noncoding RNA LIPCAR Predicts Heart Failure Outcomes in Patients Without Chronic Kidney Disease | 6.6 | 52 | Citations (PDF) |
| 171 | Towards Better Definition, Quantification and Treatment of Fibrosis in Heart Failure. A Scientific Roadmap by the Committee of Translational Research of the Heart Failure Association (HFA) of the European Society of Cardiology | 7.3 | 281 | Citations (PDF) |
| 172 | Proteomic Bioprofiles and Mechanistic Pathways of Progression to Heart Failure | 4.4 | 87 | Citations (PDF) |
| 173 | RNA-based diagnostic and therapeutic strategies for cardiovascular disease | 35.5 | 294 | Citations (PDF) |
| 174 | CircSlc8a1, breaking a vicious circle in cardiac hypertrophy | 5.5 | 11 | Citations (PDF) |
| 175 | Effects of personalized endurance training on cellular age and vascular function in middle-aged sedentary women | 2.0 | 16 | Citations (PDF) |
| 176 | Identification of miR-143 as a Major Contributor for Human Stenotic Aortic Valve Disease | 2.0 | 16 | Citations (PDF) |
| 177 | Therapeutic modulation of RNA-binding protein Rbm38 facilitates re-endothelialization after arterial injury | 5.5 | 15 | Citations (PDF) |
| 178 | The continuous heart failure spectrum: moving beyond an ejection fraction classification | 2.2 | 246 | Citations (PDF) |
| 179 | Identification of cell and disease specific microRNAs in glomerular pathologies | 4.0 | 21 | Citations (PDF) |
| 180 | Chronic kidney disease induces left ventricular overexpression of the pro-hypertrophic microRNA-212 | 3.4 | 40 | Citations (PDF) |
| 181 | Elevated levels of miR-181c and miR-633 in the CSF of patients with MS | 6.7 | 25 | Citations (PDF) |
| 182 | Serum circular RNAs act as blood-based biomarkers for hypertrophic obstructive cardiomyopathy | 3.4 | 71 | Citations (PDF) |
| 183 | Circulating microRNAs in Fabry Disease | 3.4 | 29 | Citations (PDF) |
| 184 | miR-212/132 Cluster Modulation Prevents Doxorubicin-Mediated Atrophy and Cardiotoxicity | 10.2 | 54 | Citations (PDF) |
| 185 | Noncoding RNAs: potential regulators in cardioncology | 3.5 | 19 | Citations (PDF) |
| 186 | Long Non-coding RNAs: At the Heart of Cardiac Dysfunction? | 2.8 | 116 | Citations (PDF) |
| 187 | Hypoxia-Induced MicroRNA-212/132 Alter Blood-Brain Barrier Integrity Through Inhibition of Tight Junction-Associated Proteins in Human and Mouse Brain Microvascular Endothelial Cells | 3.1 | 114 | Citations (PDF) |
| 188 | Long non-coding RNAs: A crucial part of the vasculature puzzle | 2.5 | 7 | Citations (PDF) |
| 189 | Circulating non-coding RNAs in biomarker-guided cardiovascular therapy: a novel tool for personalized medicine? | 2.2 | 94 | Citations (PDF) |
| 190 | Perspective review of optical imaging in welfare assessment in animal-based research | 2.3 | 13 | Citations (PDF) |
| 191 | Remote vitals monitoring in rodents using video recordings | 2.8 | 16 | Citations (PDF) |
| 192 | Hypoxia-induced long non-coding RNA Malat1 is dispensable for renal ischemia/reperfusion-injury | 3.4 | 82 | Citations (PDF) |
| 193 | Overexpression of preeclampsia induced microRNA-26a-5p leads to proteinuria in zebrafish | 3.4 | 29 | Citations (PDF) |
| 194 | The Innate Immune System in Chronic Cardiomyopathy: A European Society of Cardiology (Esc) Scientific Statement from the Working Group on Myocardial Function of the ESC | 7.3 | 170 | Citations (PDF) |
| 195 | Refractory angina revisited: stem cells for a growing unmet clinical need? | 2.2 | 1 | Citations (PDF) |
| 196 | Epigenetic modulation of vascular diseases: Assessing the evidence and exploring the opportunities | 2.5 | 12 | Citations (PDF) |
| 197 | Zirkuläre RNAs: neue Spieler im Kreise der Genregulation | 0.1 | 0 | Citations (PDF) |
| 198 | Non-coding RNAs in cardiovascular diseases: diagnostic and therapeutic perspectives | 2.2 | 380 | Citations (PDF) |
| 199 | Circulating microRNA-132 Levels Improve Risk Prediction for Heart Failure Hospitalization in Patients with Chronic Heart Failure | 7.3 | 78 | Citations (PDF) |
| 200 | Rationale of the FIBROTARGETS Study Designed to Identify Novel Biomarkers of Myocardial Fibrosis | 3.1 | 24 | Citations (PDF) |
| 201 | An Integrative Translational Approach to Study Heart Failure with Preserved Ejection Fraction: A Position Paper from the Working Group on Myocardial Function of the European Society of Cardiology | 7.3 | 98 | Citations (PDF) |
| 202 | Quaking Inhibits Doxorubicin-Mediated Cardiotoxicity Through Regulation of Cardiac Circular RNA Expression | 13.1 | 219 | Citations (PDF) |
| 203 | Endogenous Tumor Suppressor microRNA-193b: Therapeutic and Prognostic Value in Acute Myeloid Leukemia | 16.9 | 80 | Citations (PDF) |
| 204 | Zukunftsperspektiven der myokardialen Regeneration | 0.2 | 0 | Citations (PDF) |
| 205 | Remote Welfare Monitoring of Rodents Using Thermal Imaging | 3.0 | 40 | Citations (PDF) |
| 206 | Circulating miR-1254 predicts ventricular remodeling in patients with ST-Segment-Elevation Myocardial Infarction: A cardiovascular magnetic resonance study | 3.4 | 24 | Citations (PDF) |
| 207 | Blood-based microRNA profiling in patients with cardiac amyloidosis | 2.3 | 29 | Citations (PDF) |
| 208 | Non-coding RNAs in vascular disease – from basic science to clinical applications: scientific update from the Working Group of Myocardial Function of the European Society of Cardiology | 5.5 | 40 | Citations (PDF) |
| 209 | Complex roads from genotype to phenotype in dilated cardiomyopathy: scientific update from the Working Group of Myocardial Function of the European Society of Cardiology | 5.5 | 106 | Citations (PDF) |
| 210 | Circulating non-coding RNAs as biomarkers to predict and monitor the response to exercise: chances and hurdles | 2.2 | 7 | Citations (PDF) |
| 211 | Leptin Expression and Gene Methylation Patterns in Alcohol-Dependent Patients with Ethyltoxic Cirrhosis—Normalization After Liver Transplantation and Implications for Future Research | 1.7 | 7 | Citations (PDF) |
| 212 | Zukunftsperspektiven der myokardialen Regeneration | 0.0 | 0 | Citations (PDF) |
| 213 | Leukocyte telomere length correlates with hypertrophic cardiomyopathy severity | 3.4 | 20 | Citations (PDF) |
| 214 | Metabolic changes in hypertrophic cardiomyopathies: scientific update from the Working Group of Myocardial Function of the European Society of Cardiology | 5.5 | 96 | Citations (PDF) |
| 215 | Inflammatory cells and their non-coding RNAs as targets for treating myocardial infarction | 7.0 | 66 | Citations (PDF) |
| 216 | Circulating Noncoding RNAs as Biomarkers of Cardiovascular Disease and Injury | 13.1 | 363 | Citations (PDF) |
| 217 | Increased Proangiogenic Activity of Mobilized CD34
+
Progenitor Cells of Patients With Acute ST-Segment–Elevation Myocardial Infarction | 6.0 | 46 | Citations (PDF) |
| 218 | Long Noncoding RNAs in Pathological Cardiac Remodeling | 13.1 | 39 | Citations (PDF) |
| 219 | Therapeutic miR-21 Silencing Ameliorates Diabetic Kidney Disease in Mice | 10.2 | 190 | Citations (PDF) |
| 220 | Inhibition of miRNA-212/132 improves the reprogramming of fibroblasts into induced pluripotent stem cells by de-repressing important epigenetic remodelling factors | 0.6 | 22 | Citations (PDF) |
| 221 | Myocardial Fibrosis: Biomedical Research from Bench to Bedside | 7.3 | 364 | Citations (PDF) |
| 222 | Antagonism of profibrotic microRNA-21 improves outcome of murine chronic renal allograft dysfunction | 5.3 | 36 | Citations (PDF) |
| 223 | Epigenomic and transcriptomic approaches in the post-genomic era: path to novel targets for diagnosis and therapy of the ischaemic heart? Position Paper of the European Society of Cardiology Working Group on Cellular Biology of the Heart | 5.5 | 130 | Citations (PDF) |
| 224 | Podocytes regulate the glomerular basement membrane protein nephronectin by means of miR-378a-3p in glomerular diseases | 5.3 | 70 | Citations (PDF) |
| 225 | Inhibition of the Cardiac Fibroblast–Enriched lncRNA
Meg3
Prevents Cardiac Fibrosis and Diastolic Dysfunction | 13.1 | 337 | Citations (PDF) |
| 226 | MiR-142-3p is a paracrine mediator between T cells and endothelium during allograft rejection | 5.5 | 1 | Citations (PDF) |
| 227 | Circular RNAs in Heart Failure | 7.3 | 186 | Citations (PDF) |
| 228 | Sonic hedgehog-dependent activation of adventitial fibroblasts promotes neointima formation | 5.5 | 48 | Citations (PDF) |
| 229 | MicroRNAs in right ventricular remodelling | 5.5 | 29 | Citations (PDF) |
| 230 | miRNome Profiling of Purified Endoderm and Mesoderm Differentiated from hESCs Reveals Functions of miR-483-3p and miR-1263 for Cell-Fate Decisions | 4.4 | 28 | Citations (PDF) |
| 231 | Cardiac myocyte miR-29 promotes pathological remodeling of the heart by activating Wnt signaling | 13.7 | 222 | Citations (PDF) |
| 232 | MicroRNAs regulating superoxide dismutase 2 are new circulating biomarkers of heart failure | 3.4 | 38 | Citations (PDF) |
| 233 | MicroRNA 628-5p as a Novel Biomarker for Cardiac Allograft Vasculopathy | 2.1 | 44 | Citations (PDF) |
| 234 | Identification of miR‐126 as a new regulator of skin ageing | 2.7 | 13 | Citations (PDF) |
| 235 | P5384LNA-based miR132 inhibition is cardioprotective in a pig model of percutaneous transverse aortic constriction (pTAC) | 2.2 | 0 | Citations (PDF) |
| 236 | Porcine model of progressive cardiac hypertrophy and fibrosis with secondary postcapillary pulmonary hypertension | 6.4 | 38 | Citations (PDF) |
| 237 | A large shRNA library approach identifies lncRNA Ntep as an essential regulator of cell proliferation | 13.3 | 28 | Citations (PDF) |
| 238 | Nichtkodierende RNA | 0.7 | 4 | Citations (PDF) |
| 239 | miR-625-3p is upregulated in CD8+ T cells during early immune reconstitution after allogeneic stem cell transplantation | 2.3 | 11 | Citations (PDF) |
| 240 | Circulating miR-21 and miR-29a as Markers of Disease Severity and Etiology in Cholestatic Pediatric Liver Disease | 2.5 | 21 | Citations (PDF) |
| 241 | Chronic miR‐29 antagonism promotes favorable plaque remodeling in atherosclerotic mice | 7.1 | 73 | Citations (PDF) |
| 242 | Mitochondrial long noncoding RNAs as blood based biomarkers for cardiac remodeling in patients with hypertrophic cardiomyopathy | 3.5 | 37 | Citations (PDF) |
| 243 | Long noncoding RNAs in kidney and cardiovascular diseases | 32.8 | 307 | Citations (PDF) |
| 244 | Preclinical Development of a MicroRNA-Based Therapy for Elderly Patients With Myocardial Infarction | 2.3 | 117 | Citations (PDF) |
| 245 | RNA Profiling in Human and Murine Transplanted Hearts: Identification and Validation of Therapeutic Targets for Acute Cardiac and Renal Allograft Rejection | 4.5 | 60 | Citations (PDF) |
| 246 | Non-coding RNAs in Development and Disease: Background, Mechanisms, and Therapeutic Approaches | 25.4 | 1,651 | Citations (PDF) |
| 247 | Circulating long-non coding RNAs as biomarkers of left ventricular diastolic function and remodelling in patients with well-controlled type 2 diabetes | 3.4 | 148 | Citations (PDF) |
| 248 | Stiff matrix induces switch to pure β-cardiac myosin heavy chain expression in human ESC-derived cardiomyocytes | 7.0 | 66 | Citations (PDF) |
| 249 | Long Noncoding RNAs in Cardiovascular Pathology, Diagnosis, and Therapy | 18.0 | 226 | Citations (PDF) |
| 250 | MicroRNA-Based Therapy of GATA2-Deficient Vascular Disease | 18.0 | 56 | Citations (PDF) |
| 251 | Regulator of G-Protein Signaling 5 Prevents Smooth Muscle Cell Proliferation and Attenuates Neointima Formation | 6.0 | 38 | Citations (PDF) |
| 252 | Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition) | 13.7 | 5,032 | Citations (PDF) |
| 253 | Non-coding RNAs as orchestrators of autophagic processes | 3.8 | 26 | Citations (PDF) |
| 254 | Deregulation of microRNA-181c in cerebrospinal fluid of patients with clinically isolated syndrome is associated with early conversion to relapsing–remitting multiple sclerosis | 3.9 | 50 | Citations (PDF) |
| 255 | Long noncoding RNA
Chast
promotes cardiac remodeling | 12.5 | 357 | Citations (PDF) |
| 256 | miR-21 promotes fibrosis in an acute cardiac allograft transplantation model | 5.5 | 71 | Citations (PDF) |
| 257 | Non-coding RNAs as modulators of the cardiac fibroblast phenotype | 3.8 | 46 | Citations (PDF) |
| 258 | Development of Long Noncoding RNA-Based Strategies to Modulate Tissue Vascularization | 2.3 | 112 | Citations (PDF) |
| 259 | Facts and Updates About Cardiovascular Non-Coding Rnas in Heart Failure | 3.1 | 14 | Citations (PDF) |
| 260 | Searching for New Mechanisms of Myocardial Fibrosis with Diagnostic and/or Therapeutic Potential | 7.3 | 127 | Citations (PDF) |
| 261 | Intercellular Communication Lessons in Heart Failure | 7.3 | 55 | Citations (PDF) |
| 262 | Circulating microRNAs and Outcome in Patients with Acute Heart Failure | 2.3 | 78 | Citations (PDF) |
| 263 | Enabling [18F]-bicyclo[6.1.0]nonyne for oligonucleotide conjugation for positron emission tomography applications: [18F]-anti-microRNA-21 as an example | 3.4 | 18 | Citations (PDF) |
| 264 | Osteopontin is indispensible for AP1-mediated angiotensin II-related miR-21 transcription during cardiac fibrosis | 2.2 | 134 | Citations (PDF) |
| 265 | Deciphering the microRNA signature of pathological cardiac hypertrophy by engineered heart tissue- and sequencing-technology | 3.8 | 45 | Citations (PDF) |
| 266 | Antiandrogenic Therapy With Finasteride Attenuates Cardiac Hypertrophy and Left Ventricular Dysfunction | 18.0 | 75 | Citations (PDF) |
| 267 | Noncoding RNAs as regulators of cardiomyocyte proliferation and death | 3.8 | 59 | Citations (PDF) |
| 268 | Long Noncoding RNAs and MicroRNAs in Cardiovascular Pathophysiology | 13.1 | 375 | Citations (PDF) |
| 269 | MicroRNA Signatures Differentiate Preserved from Reduced Ejection Fraction Heart Failure | 7.3 | 210 | Citations (PDF) |
| 270 | Blood-based microRNA signatures differentiate various forms of cardiac hypertrophy | 2.2 | 98 | Citations (PDF) |
| 271 | Zinc-α2-Glycoprotein Exerts Antifibrotic Effects in Kidney and Heart | 0.4 | 55 | Citations (PDF) |
| 272 | Impairment of Wound Healing in Patients With Type 2 Diabetes Mellitus Influences Circulating MicroRNA Patterns via Inflammatory Cytokines | 6.0 | 150 | Citations (PDF) |
| 273 | Long noncoding RNAs in cardiac development and ageing | 35.5 | 328 | Citations (PDF) |
| 274 | Long Noncoding RNAs in Urine Are Detectable and May Enable Early Detection of Acute T Cell–Mediated Rejection of Renal Allografts | 1.1 | 69 | Citations (PDF) |
| 275 | Antiageing concepts and cardiovascular disease | 2.2 | 1 | Citations (PDF) |
| 276 | Adrenergic Repression of the Epigenetic Reader MeCP2 Facilitates Cardiac Adaptation in Chronic Heart Failure | 13.1 | 68 | Citations (PDF) |
| 277 | Bioinformatics of cardiovascular miRNA biology | 3.8 | 23 | Citations (PDF) |
| 278 | Circulating Long Noncoding RNA TapSAKI Is a Predictor of Mortality in Critically Ill Patients with Acute Kidney Injury | 1.1 | 107 | Citations (PDF) |
| 279 | MicroRNAs in Serum and Bile of Patients with Primary Sclerosing Cholangitis and/or Cholangiocarcinoma | 2.3 | 97 | Citations (PDF) |
| 280 | Cardiac fibroblast–derived microRNA passenger strand-enriched exosomes mediate cardiomyocyte hypertrophy | 10.6 | 921 | Citations (PDF) |
| 281 | MicroRNA 628-5p as a Novel Biomarker for Cardiac Allograft Vasculopathy (CAV). | 2.1 | 0 | Citations (PDF) |
| 282 | Impact of a Met(11)Thr single nucleotide polymorphism of surfactant protein D on allergic airway inflammation in a murine asthma model | 1.5 | 10 | Citations (PDF) |
| 283 | Heterocellular signalling and crosstalk in the heart in ischaemia and heart failure | 5.5 | 18 | Citations (PDF) |
| 284 | DIABETES EXPERIMENTAL | 0.8 | 0 | Citations (PDF) |
| 285 | Summary of Basic Science Activities at the European Society of Cardiology Congress in Barcelona 2014 | 3.1 | 0 | Citations (PDF) |
| 286 | A signature of circulating microRNAs differentiates takotsubo cardiomyopathy from acute myocardial infarction | 2.2 | 269 | Citations (PDF) |
| 287 | Prevention of liver cancer cachexia-induced cardiac wasting and heart failure | 2.2 | 196 | Citations (PDF) |
| 288 | MicroRNAs in the bile of patients with biliary strictures after liver transplantation | 2.5 | 27 | Citations (PDF) |
| 289 | ESC Working Group on Myocardial Function Position Paper: How to Study the Right Ventricle in Experimental Models | 7.3 | 14 | Citations (PDF) |
| 290 | Towards novel theranostic approaches in cardiac transplantation medicine | 2.2 | 3 | Citations (PDF) |
| 291 | Inhibition of proteasome‐mediated glucocorticoid receptor degradation restores nitric oxide bioavailability in myocardial endothelial cellsin vitro | 2.6 | 9 | Citations (PDF) |
| 292 | MicroRNAs play a role in spontaneous recovery from acute liver failure | 10.1 | 89 | Citations (PDF) |
| 293 | Targeting Myocardial Remodelling to Develop Novel Therapies for Heart Failure | 7.3 | 102 | Citations (PDF) |
| 294 | LC–MS/MS and GC–MS/MS measurement of plasma and urine di-paracetamol and 3-nitro-paracetamol: Proof-of-concept studies on a novel human model of oxidative stress based on oral paracetamol administration | 2.6 | 10 | Citations (PDF) |
| 295 | MicroRNA-based therapy in cardiology | 0.7 | 13 | Citations (PDF) |
| 296 | Circulating Long Noncoding RNA, LIPCAR, Predicts Survival in Patients With Heart Failure | 13.1 | 608 | Citations (PDF) |
| 297 | microRNA Therapeutics in Cardiovascular Disease Models | 11.8 | 97 | Citations (PDF) |
| 298 | Circulating microRNAs for Predicting and Monitoring Response to Mechanical Circulatory Support from a Left Ventricular Assist Device | 7.3 | 58 | Citations (PDF) |
| 299 | Regulatory RNAs and paracrine networks in the heart | 5.5 | 67 | Citations (PDF) |
| 300 | Functional MicroRNA Library Screening Identifies the HypoxaMiR MiR-24 as a Potent Regulator of Smooth Muscle Cell Proliferation and Vascularization | 6.3 | 48 | Citations (PDF) |
| 301 | MicroRNAs associated with ischemia-reperfusion injury and cardioprotection by ischemic pre- and postconditioning: protectomiRs | 3.5 | 120 | Citations (PDF) |
| 302 | TISSUE INJURY AND REPAIR | 0.8 | 1 | Citations (PDF) |
| 303 | Endothelial function in contemporary patients with repaired coarctation of aortaHeart, 2014, 100, 1696-1701 | 3.9 | 24 | Citations (PDF) |
| 304 | Noncoding RNAs and myocardial fibrosis | 35.5 | 177 | Citations (PDF) |
| 305 | Vascular importance of the miR-212/132 cluster | 2.2 | 80 | Citations (PDF) |
| 306 | Circulating micrornas as potential biomarkers of aerobic exercise capacity | 3.5 | 222 | Citations (PDF) |
| 307 | Non-coding RNAs in cardiovascular ageing | 11.6 | 43 | Citations (PDF) |
| 308 | Diabetes-Associated MicroRNAs in Pediatric Patients With Type 1 Diabetes Mellitus: A Cross-Sectional Cohort Study | 4.0 | 145 | Citations (PDF) |
| 309 | Analytical approaches in microRNA therapeutics | 2.6 | 14 | Citations (PDF) |
| 310 | Novel Biomarkers for Acute Myocardial Infarction: Is MicroRNA the New Kid on the Block? | 1.1 | 17 | Citations (PDF) |
| 311 | MicroRNA-24 Antagonism Prevents Renal Ischemia Reperfusion Injury | 0.4 | 143 | Citations (PDF) |
| 312 | Trapping of NAPQI, the intermediate toxic paracetamol metabolite, by aqueous sulfide (S2−) and analysis by GC–MS/MS | 2.6 | 7 | Citations (PDF) |
| 313 | Cardiac myocyte–secreted cAMP exerts paracrine action via adenosine receptor activation | 10.6 | 79 | Citations (PDF) |
| 314 | MicroRNAs in Right Ventricular (dys)function (2013 Grover Conference Series) | 2.1 | 23 | Citations (PDF) |
| 315 | Regulation of cardiac and renal ischemia–reperfusion injury by microRNAs | 3.7 | 67 | Citations (PDF) |
| 316 | Circulating miR-423_5p fails as a biomarker for systemic ventricular function in adults after atrial repair for transposition of the great arteries | 2.2 | 55 | Citations (PDF) |
| 317 | Non-coding RNAs in Cardiac Remodeling and Heart Failure | 13.1 | 240 | Citations (PDF) |
| 318 | Macrophage MicroRNA-155 Promotes Cardiac Hypertrophy and Failure | 18.0 | 245 | Citations (PDF) |
| 319 | MicroRNAs in Myocardial Infarction | 6.0 | 124 | Citations (PDF) |
| 320 | MicroRNAs in platelet physiology and pathology | 0.8 | 24 | Citations (PDF) |
| 321 | MiR-378 Controls Cardiac Hypertrophy by Combined Repression of Mitogen-Activated Protein Kinase Pathway Factors | 18.0 | 230 | Citations (PDF) |
| 322 | MicroRNA and disease models: focus on cardiac fibrosis | 1.6 | 0 | Citations (PDF) |
| 323 | Nfat and miR-25 cooperate to reactivate the transcription factor Hand2 in heart failure | 16.3 | 133 | Citations (PDF) |
| 324 | Circulating miR-133a and miR-423-5p fail as biomarkers for left ventricular remodeling after myocardial infarction | 2.2 | 98 | Citations (PDF) |
| 325 | TWIST1 regulates the activity of ubiquitin proteasome system via the miR-199/214 cluster in human end-stage dilated cardiomyopathy | 2.2 | 50 | Citations (PDF) |
| 326 | MicroRNA-Mediated Epigenetic Silencing of Sirtuin1 Contributes to Impaired Angiogenic Responses | 13.1 | 58 | Citations (PDF) |
| 327 | MicroRNAs in Idiopathic Childhood Nephrotic Syndrome | 1.1 | 6 | Citations (PDF) |
| 328 | MicroRNA-155 promotes acute cardiac allograft rejection in human and mice | 2.2 | 0 | Citations (PDF) |
| 329 | Activation of the miR-17 Family and miR-21 During Murine Kidney Ischemia-Reperfusion Injury | 4.6 | 55 | Citations (PDF) |
| 330 | RNA-binding motif protein 38 inhibits re-endothelialization following vascular injury | 2.2 | 0 | Citations (PDF) |
| 331 | Regulated microRNAs in the CSF of patients with multiple sclerosis | 1.0 | 157 | Citations (PDF) |
| 332 | MicroRNAs in Immunität und Organtransplantation | 0.0 | 0 | Citations (PDF) |
| 333 | Novel techniques and targets in cardiovascular microRNA research | 5.5 | 66 | Citations (PDF) |
| 334 | Review focus on the role of microRNA in cardiovascular biology and disease | 5.5 | 63 | Citations (PDF) |
| 335 | Circulating and Urinary microRNAs in Kidney Disease | 4.2 | 91 | Citations (PDF) |
| 336 | MicroRNAs deciding cardiac stem cell fate | 3.8 | 2 | Citations (PDF) |
| 337 | MicroRNA‐Based Therapeutic Approaches in the Cardiovascular System | 5.3 | 12 | Citations (PDF) |
| 338 | SERCA2a gene therapy restores microRNA-1 expression in heart failure via an Akt/FoxO3A-dependent pathway | 2.2 | 137 | Citations (PDF) |
| 339 | Transforming Growth Factor-β–Induced Endothelial-to-Mesenchymal Transition Is Partly Mediated by MicroRNA-21 | 6.0 | 288 | Citations (PDF) |
| 340 | A phenotypic screen to identify hypertrophy-modulating microRNAs in primary cardiomyocytes | 3.8 | 109 | Citations (PDF) |
| 341 | Urinary asymmetric dimethylarginine (ADMA) is a predictor of mortality risk in patients with coronary artery disease | 2.2 | 36 | Citations (PDF) |
| 342 | Exosomes: New players in cell–cell communication | 2.6 | 471 | Citations (PDF) |
| 343 | Novel non‐coding RNA‐based therapeutic approaches to prevent statin‐induced liver damage | 7.1 | 4 | Citations (PDF) |
| 344 | MicroRNAs in platelet biogenesis and function | 4.1 | 51 | Citations (PDF) |
| 345 | The miRNA-212/132 family regulates both cardiac hypertrophy and cardiomyocyte autophagy | 13.7 | 588 | Citations (PDF) |
| 346 | Circulating MicroRNAs Are Not Eliminated by Hemodialysis | 2.3 | 52 | Citations (PDF) |
| 347 | Aromatase Inhibition Attenuates Desflurane-Induced Preconditioning against Acute Myocardial Infarction in Male Mouse Heart In Vivo | 2.3 | 37 | Citations (PDF) |
| 348 | Circulating microRNAs in Patients with Shiga-Toxin-Producing E. coli O104:H4 Induced Hemolytic Uremic Syndrome | 2.3 | 9 | Citations (PDF) |
| 349 | MicroRNAs in diabetes and diabetes-associated complications | 3.3 | 57 | Citations (PDF) |
| 350 | miRNAs involved in the generation, maintenance, and differentiation of pluripotent cells | 3.7 | 22 | Citations (PDF) |
| 351 | MicroRNAs bei Nierenerkrankungen: kleine Moleküle mit großer Wirkung | 0.2 | 0 | Citations (PDF) |
| 352 | Epigenetic modifications in cardiovascular disease | 7.0 | 128 | Citations (PDF) |
| 353 | Role of miR-21 in the pathogenesis of atrial fibrosis | 7.0 | 252 | Citations (PDF) |
| 354 | Microvesicles as Novel Biomarkers and Therapeutic Targets in Transplantation Medicine | 4.5 | 60 | Citations (PDF) |
| 355 | Cardiovascular Importance of the MicroRNA‐23/27/24 Family | 1.6 | 90 | Citations (PDF) |
| 356 | MicroRNA therapeutics in cardiovascular medicine | 7.1 | 180 | Citations (PDF) |
| 357 | MicroRNA Target Sites as Genetic Tools to Enhance Promoter-Reporter Specificity for the Purification of Pancreatic Progenitor Cells from Differentiated Embryonic Stem Cells | 5.6 | 8 | Citations (PDF) |
| 358 | MicroRNA-22 increases senescence and activates cardiac fibroblasts in the aging heart | 3.0 | 176 | Citations (PDF) |
| 359 | Pathologic endothelial response and impaired function of circulating angiogenic cells in patients with Fabry disease | 7.0 | 10 | Citations (PDF) |
| 360 | Absence of microRNA‐155 protects against pressure overload‐induced cardiac inflammation and failure | 0.6 | 0 | Citations (PDF) |
| 361 | Regulation and function of miRNA-21 in health and disease | 3.3 | 581 | Citations (PDF) |
| 362 | Organic Nitrates Differentially Modulate Circulating Endothelial Progenitor Cells and Endothelial Function in Patients with Symptomatic Coronary Artery Disease | 6.3 | 15 | Citations (PDF) |
| 363 | Glucocorticoid Insensitivity at the Hypoxic Blood–Brain Barrier Can Be Reversed by Inhibition of the Proteasome | 5.9 | 85 | Citations (PDF) |
| 364 | MicroRNAs as mediators and therapeutic targets in chronic kidney disease | 32.8 | 197 | Citations (PDF) |
| 365 | Diagnostic and prognostic impact of six circulating microRNAs in acute coronary syndrome | 3.8 | 379 | Citations (PDF) |
| 366 | Identification of cardiovascular microRNA targetomes | 3.8 | 16 | Citations (PDF) |
| 367 | miRNA screening reveals a new miRNA family stimulating iPS cell generation via regulation of Meox2 | 5.2 | 91 | Citations (PDF) |
| 368 | Urinary miR-210 as a Mediator of Acute T-Cell Mediated Rejection in Renal Allograft Recipients | 4.5 | 192 | Citations (PDF) |
| 369 | MicroRNAs and vascular (dys)function | 2.5 | 55 | Citations (PDF) |
| 370 | Critical Role of the Nitric Oxide/Reactive Oxygen Species Balance in Endothelial Progenitor Dysfunction | 6.3 | 88 | Citations (PDF) |
| 371 | Biogenesis and Regulation of Cardiovascular MicroRNAs | 13.1 | 158 | Citations (PDF) |
| 372 | MicroRNA-24 Regulates Vascularity After Myocardial Infarction | 18.0 | 381 | Citations (PDF) |
| 373 | Circulating miR-210 Predicts Survival in Critically Ill Patients with Acute Kidney Injury | 4.2 | 192 | Citations (PDF) |
| 374 | Impairment of endothelial progenitor cell function and vascularization capacity by aldosterone in mice and humans | 2.2 | 53 | Citations (PDF) |
| 375 | TLR-4+ peripheral blood monocytes and cardiovascular events in patients with chronic kidney disease--a prospective follow-up study | 0.8 | 15 | Citations (PDF) |
| 376 | Signal transducer and activator of transcription 3-mediated regulation of miR-199a-5p links cardiomyocyte and endothelial cell function in the heart: a key role for ubiquitin-conjugating enzymes | 2.2 | 131 | Citations (PDF) |
| 377 | Conversion from conventional in-centre thrice-weekly haemodialysis to short daily home haemodialysis ameliorates uremia-associated clinical parameters | 1.4 | 11 | Citations (PDF) |
| 378 | MicroRNAs in Hypertension: Mechanisms and Therapeutic Targets | 4.7 | 133 | Citations (PDF) |
| 379 | Comparison of different miR-21 inhibitor chemistries in a cardiac disease model | 10.6 | 107 | Citations (PDF) |
| 380 | EMT, EndMT, PMT – Mechanismen der interstitiellen Fibrose | 0.2 | 0 | Citations (PDF) |
| 381 | Endothelial Progenitor Cells in Pulmonary Arterial Hypertension | 7.2 | 42 | Citations (PDF) |
| 382 | Measurement and diagnostic use of hepatic cytochrome P450 metabolism of oleic acid in liver disease | 3.9 | 12 | Citations (PDF) |
| 383 | miR-212 and miR-132 are required for epithelial stromal interactions necessary for mouse mammary gland development | 25.2 | 145 | Citations (PDF) |
| 384 | Resveratrol Reverses Endothelial Nitric-Oxide Synthase Uncoupling in Apolipoprotein E Knockout Mice | 3.3 | 178 | Citations (PDF) |
| 385 | MicroRNAs As Circulating Biomarkers for Heart Failure: Questions About MiR-423-5p | 13.1 | 33 | Citations (PDF) |
| 386 | Short Communication: Asymmetric Dimethylarginine Impairs Angiogenic Progenitor Cell Function in Patients With Coronary Artery Disease Through a MicroRNA-21–Dependent Mechanism | 13.1 | 183 | Citations (PDF) |
| 387 | Circulating MicroRNAs as Biomarkers and Potential Paracrine Mediators of Cardiovascular Disease | 3.8 | 273 | Citations (PDF) |
| 388 | Response to Letter Regarding Article, “Circulating Endothelial Progenitor Cells in Patients With Eisenmenger Syndrome and Idiopathic Pulmonary Arterial Hypertension” | 18.0 | 2 | Citations (PDF) |
| 389 | Innovative molekulare Therapiestrategien in der Kardiologie | 0.2 | 0 | Citations (PDF) |
| 390 | No effects of human ghrelin on cardiac function despite profound effects on body composition in a rat model of heart failure | 2.2 | 44 | Citations (PDF) |
| 391 | MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts | 37.9 | 2,283 | Citations (PDF) |
| 392 | Effect of Intravenous Iron Sucrose on Exercise Tolerance in Anemic and Nonanemic Patients With Symptomatic Chronic Heart Failure and Iron Deficiency | 2.3 | 541 | Citations (PDF) |
| 393 | Effects of Physical Exercise on Myocardial Telomere-Regulating Proteins, Survival Pathways, and Apoptosis | 2.3 | 228 | Citations (PDF) |
| 394 | MicroRNAs in cardiac hypertrophy and failure | 1.1 | 3 | Citations (PDF) |
| 395 | Mechanisms underlying recoupling of eNOS by HMG-CoA reductase inhibition in a rat model of streptozotocin-induced diabetes mellitus | 1.5 | 124 | Citations (PDF) |
| 396 | Increase of Pro-Inflammatory Cytokine Expression in Non-Demyelinating Early Cerebral Lesions in Nervous Canine Distemper | 1.1 | 23 | Citations (PDF) |
| 397 | Circulating Endothelial Progenitor Cells in Patients With Eisenmenger Syndrome and Idiopathic Pulmonary Arterial Hypertension | 18.0 | 212 | Citations (PDF) |
| 398 | LOX-1 Receptor Blockade Abrogates oxLDL-induced Oxidative DNA Damage and Prevents Activation of the Transcriptional Repressor Oct-1 in Human Coronary Arterial Endothelium | 2.2 | 61 | Citations (PDF) |
| 399 | MicroRNAs: novel regulators in cardiac development and disease | 5.5 | 333 | Citations (PDF) |
| 400 | Letter by Thum et al Regarding Article, “Oxidant Stress Impairs In Vivo Reendothelialization Capacity of Endothelial Progenitor Cells From Patients With Type 2 Diabetes Mellitus: Restoration by the Peroxisome Proliferator- Activated Receptor-γ Agonist Rosiglitazone” | 18.0 | 1 | Citations (PDF) |
| 401 | Improvement in Left Ventricular Remodeling by the Endothelial Nitric Oxide Synthase Enhancer AVE9488 After Experimental Myocardial Infarction | 18.0 | 118 | Citations (PDF) |
| 402 | Prevention of cardiac hypertrophy and failure in vivo by a novel microRNA antagonist | 0.0 | 0 | Citations (PDF) |
| 403 | Age-Dependent Impairment of Endothelial Progenitor Cells Is Corrected by Growth Hormone Mediated Increase of Insulin-Like Growth Factor-1 | 13.1 | 282 | Citations (PDF) |
| 404 | Growth Hormone Treatment Improves Markers of Systemic Nitric Oxide Bioavailability via Insulin-Like Growth Factor-I | 4.0 | 61 | Citations (PDF) |
| 405 | Differential Effects of Organic Nitrates on Endothelial Progenitor Cells Are Determined by Oxidative Stress | 6.0 | 68 | Citations (PDF) |
| 406 | Tissue-Specific Effects of the Nuclear Factor κB Subunit p50 on Myocardial Ischemia-Reperfusion Injury | 3.4 | 69 | Citations (PDF) |
| 407 | MicroRNAs in the Human Heart | 18.0 | 887 | Citations (PDF) |
| 408 | Microarray-based gene expression profiling to elucidate cellular responses to nitric oxide—A review from an analytical and biomedical point of view | 2.6 | 12 | Citations (PDF) |
| 409 | Accurate quantification of dimethylamine (DMA) in human urine by gas chromatography–mass spectrometry as pentafluorobenzamide derivative: Evaluation of the relationship between DMA and its precursor asymmetric dimethylarginine (ADMA) in health and disease | 2.6 | 88 | Citations (PDF) |
| 410 | GC–MS assay for hepatic DDAH activity in diabetic and non-diabetic rats by measuring dimethylamine (DMA) formed from asymmetric dimethylarginine (ADMA): Evaluation of the importance of S-nitrosothiols as inhibitors of DDAH activity in vitro and in vivo in humans | 2.6 | 28 | Citations (PDF) |
| 411 | Endothelial progenitor cell dysfunction: mechanisms and therapeutic approaches | 3.0 | 18 | Citations (PDF) |
| 412 | MicroRNAs in the broken heart | 3.0 | 26 | Citations (PDF) |
| 413 | Detection of early signals of hepatotoxicity by gene expression profiling studies with cultures of metabolically competent human hepatocytes | 5.8 | 27 | Citations (PDF) |
| 414 | 40 MicroRNAs in the human heart: a clue to fetal gene reprogramming in heart failure | 0.0 | 1 | Citations (PDF) |
| 415 | Sports or statins for atheroprotection? New insight from Kruppel-like factor 2 | 5.5 | 3 | Citations (PDF) |
| 416 | Bone marrow molecular alterations after myocardial infarction: Impact on endothelial progenitor cells | 5.5 | 103 | Citations (PDF) |
| 417 | Expression of Xenobiotic Metabolizing Enzymes in Different Lung Compartments of Smokers and Nonsmokers | 8.3 | 114 | Citations (PDF) |
| 418 | Cardiac regeneration by progenitor cells - bedside before bench? | 3.0 | 4 | Citations (PDF) |
| 419 | ADMA, Endothelial Progenitor Cells, and Cardiovascular Risk | 13.1 | 7 | Citations (PDF) |
| 420 | Spotlight on endothelial progenitor cell inhibitors: short review | 2.4 | 8 | Citations (PDF) |
| 421 | Clostridium difficile Toxin A Induces Expression of the Stress-induced Early Gene Product RhoB | 2.2 | 64 | Citations (PDF) |
| 422 | Spotlight on endothelial progenitor cell inhibitors: short review | 2.4 | 8 | Citations (PDF) |
| 423 | Mobilization of bone marrow-derived stem cells after myocardial infarction and left ventricular function: simply effects of optimized drug treatment? | 2.2 | 3 | Citations (PDF) |
| 424 | Suppression of Endothelial Progenitor Cells in Human Coronary Artery Disease by the Endogenous Nitric Oxide Synthase Inhibitor Asymmetric Dimethylarginine | 2.3 | 223 | Citations (PDF) |
| 425 | The Dying Stem Cell Hypothesis | 2.3 | 196 | Citations (PDF) |
| 426 | Growth hormone regulates vascular function—what we know from bench and bedside | 2.0 | 6 | Citations (PDF) |
| 427 | ANDROGEN METABOLISM IN THYMUS OF FETAL AND ADULT RATS | 3.6 | 9 | Citations (PDF) |
| 428 | Mechanistic Role of Cytochrome P450 Monooxygenases in Oxidized Low-Density Lipoprotein–Induced Vascular Injury | 13.1 | 66 | Citations (PDF) |
| 429 | Endogenous Nitric Oxide Synthesis Inhibitor Asymmetric Dimethyl
l
-Arginine Accelerates Endothelial Cell Senescence | 6.0 | 140 | Citations (PDF) |
| 430 | Metabolism of verapamil: 24 new phase I and phase II metabolites identified in cell cultures of rat hepatocytes by liquid chromatography–tandem mass spectrometry | 2.6 | 25 | Citations (PDF) |
| 431 | Growth hormone induces eNOS expression and nitric oxide release in a cultured human endothelial cell line | 2.7 | 52 | Citations (PDF) |
| 432 | A rapid and simple CYP2D6 genotyping assay—case study with the analgetic tramadol | 9.1 | 28 | Citations (PDF) |
| 433 | VERAPAMIL: METABOLISM IN CULTURES OF PRIMARY HUMAN CORONARY ARTERIAL ENDOTHELIAL CELLS | 3.6 | 28 | Citations (PDF) |
| 434 | Hallmarks of ion channel gene expression in end‐stage heart failure | 0.6 | 159 | Citations (PDF) |
| 435 | Verapamil: identification of novel metabolites in cultures of primary human hepatocytes and human urine by LC-MS n and LC-NMR | 1.1 | 30 | Citations (PDF) |
| 436 | Testosterone, cytochrome P450, and cardiac hypertrophy | 0.6 | 125 | Citations (PDF) |
| 437 | PCBs alter gene expression of nuclear transcription factors and other heart-specific genes in cultures of primary cardiomyocytes: possible implications for cardiotoxicity | 1.1 | 22 | Citations (PDF) |
| 438 | Identification of Major CYP2C9 and CYP2C19 Polymorphisms by Fluorescence Resonance Energy Transfer Analysis | 1.1 | 13 | Citations (PDF) |
| 439 | Verapamil: new insight into the molecular mechanism of drug oxidation in the human heart | 3.7 | 24 | Citations (PDF) |
| 440 | Aroclor 1254 Modulates Gene Expression of Nuclear Transcription Factors: Implications for Albumin Gene Transcription and Protein Synthesis in Rat Hepatocyte Cultures | 3.2 | 24 | Citations (PDF) |
| 441 | REPROGRAMMING OF GENE EXPRESSION IN CULTURED CARDIOMYOCYTES AND IN EXPLANTED HEARTS BY THE MYOSIN ATPASE INHIBITOR BUTANEDIONE MONOXIME | 2.1 | 12 | Citations (PDF) |
| 442 | Butanedione Monoxime Increases the Viability and Yield of Adult Cardiomyocytes in Primary Cultures | 3.4 | 18 | Citations (PDF) |
| 443 | Induction of nuclear transcription factors, cytochrome P450 monooxygenases, and glutathione S-transferase alpha gene expression in Aroclor 1254-treated rat hepatocyte cultures11Abbreviations: Ah, aryl hydrocarbon; c/EBP, CCAAT/enhancer-binding protein; cDNA, complementary DNA CYP, cytochrome P450; EROD, ethoxyresorufin-O-deethylase; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; GSTA, glutathione S-transferase alpha; HNF, hepatic nuclear factor; RT–PCR, reverse transcription–polymerase chain reaction; and | 5.1 | 38 | Citations (PDF) |
| 444 | Cytochrome P450 mono-oxygenase gene expression and protein activity in cultures of adult cardiomyocytes of the rat | 6.3 | 54 | Citations (PDF) |
| 445 | Molecular Diagnosis of a Familial Nonhemolytic Hyperbilirubinemia (Gilbert's Syndrome) in Healthy Subjects | 10.1 | 84 | Citations (PDF) |
| 446 | Cellular dedifferentiation of endothelium is linked to activation and silencing of certain nuclear transcription factors: implications for endothelial dysfunction and vascular biology | 0.6 | 64 | Citations (PDF) |
| 447 | Isolation and cultivation of Ca2+tolerant cardiomyocytes from the adult rat: improvements and applications | 1.1 | 12 | Citations (PDF) |
| 448 | Gene expression in distinct regions of the heart | 62.1 | 183 | Citations (PDF) |
| 449 | Pharmacotherapy of cardiovascular diseases from herbs and pills to nucleic acids | 2.2 | 3 | Citations (PDF) |
| 450 | Left ventricular hypertrophy and myocardial fibrosis in heart failure with preserved ejection fraction: mechanisms and treatment | 2.2 | 21 | Citations (PDF) |
| 451 | Telomerase
modRNA
Offers a Novel
RNA
‐Based Approach to Treat Human Pulmonary Fibrosis | 6.8 | 1 | Citations (PDF) |
| 452 | A circular RNA derived from the ryanodine receptor 2 locus controls cardiac hypertrophy and calcium handling | 5.5 | 3 | Citations (PDF) |
| 453 | Prostaglandin D2 Synthase: A Novel Player in the Pathological Signaling Mechanism of the Aldosterone–Mineralocorticoid Receptor Pathway in the Heart | 4.6 | 0 | Citations (PDF) |
| 454 | Increase in mechanical load and pro-fibrotic stimulation leads to fibrotic and hypertrophic remodeling in porcine living myocardial slices | 3.4 | 0 | Citations (PDF) |
| 455 | SARS-CoV-2-infected cardiomyocytes exhibit upregulated necroptosis, but no evidence of mitochondrial permeability transition | 1.5 | 1 | Citations (PDF) |
| 456 | Extracellular BRICK1 drives heart repair after myocardial infarction in mice | 12.5 | 1 | Citations (PDF) |
| 457 | Pharmacological inhibition of myosin reduces the cytotoxic effect of a Lys49 PLA2-like myotoxin on human and rat cardiac muscle | 6.6 | 0 | Citations (PDF) |
| 458 | mRNA-based SARS-CoV-2 vaccines: intracellular processing and aggregation of the encoded spike protein as a mechanistic contributor to cardiac cellular stress | 4.9 | 0 | Citations (PDF) |
| 459 | Preclinical development of a Meg3 ASO inhibitor for the treatment of cardiac fibrosis | 7.3 | 0 | Citations (PDF) |
| 460 | RNA splicing and cardiovascular disease: a guide for cardiologists | 2.2 | 0 | Citations (PDF) |
| 461 | Looking beyond one's own nose: novel therapies based on noncoding RNAs | 3.7 | 0 | Citations (PDF) |
